<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=1200, user-scalable=yes, initial-scale=0.4, minimum-scale=0.1">
    <title>6-APB - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
        
        // Force desktop behavior by overriding mobile detection
        window.isMobile = false;
        window.isDesktop = true;
        
        // Override any mobile detection functions
        if (window.matchMedia) {
            const originalMatchMedia = window.matchMedia;
            window.matchMedia = function(query) {
                // Force desktop media queries to always match for min-width
                // and mobile queries to never match
                if (query.includes('max-width') && (query.includes('768px') || query.includes('480px'))) {
                    return { matches: false, addListener: function() {}, removeListener: function() {} };
                }
                if (query.includes('min-width')) {
                    return { matches: true, addListener: function() {}, removeListener: function() {} };
                }
                return originalMatchMedia.call(this, query);
            };
        }
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/empathogens/">Empathogens</a> ‚ÜÅE<span>6-APB</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üî• 6-APB</h1>
        <h2 class="chemical-name">6-(2-Aminopropyl)benzofuran</h2>
          
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="6-APB" 
                data-category="Empathogens" 
                data-chemical="6-(2-Aminopropyl)benzofuran">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>Benzofury</span> ‚Ä¢ <span>Benzo Fury</span> ‚Ä¢ <span>6-APB</span> ‚Ä¢ <span>Benzofuran</span>
            </div>
            <div class="name-category">
              <h4>Research Chemical Names</h4>
              <span>Fury</span> ‚Ä¢ <span>Legal E</span> ‚Ä¢ <span>Legal Ecstasy</span> ‚Ä¢ <span>Plant Food</span>
            </div>
            <div class="name-category">
              <h4>Chemical Names</h4>
              <span>6-APDB analog</span> ‚Ä¢ <span>Benzofuranylpropanamine</span> ‚Ä¢ <span>BF-6</span>
            </div>
            <div class="name-category">
              <h4>Scientific Codes</h4>
              <span>CAS: 286834-85-3</span> ‚Ä¢ <span>Benzofury-6</span> ‚Ä¢ <span>APB-6</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category benzofuran-empathogen">Benzofuran Empathogen</span>
          <span class="legal-status controlled">Controlled</span>
          <span class="duration long">6-10 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/6-apb.jpg" alt="6-APB crystals and molecular structure" class="substance-photo">
          <div class="image-caption">
            <p><strong>Extended Duration:</strong> Longer-lasting than MDMA with similar empathogenic effects but increased body load</p>
          </div>
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÅH‚ÇÅ‚ÇÉNO</p>
            <p>MW: 175.23 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure 6-APB (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine to coarse crystalline powder</li>
            <li><strong>Odor:</strong> Chemical smell, sometimes described as slightly floral</li>
            <li><strong>Taste:</strong> Extremely bitter, chemical, unpleasant</li>
            <li><strong>Solubility:</strong> Moderately soluble in water, better in alcohol</li>
          </ul>
        </div>
        
        <div class="research-chemical-forms">
          <h4>Research Chemical Market Forms</h4>
          <ul>
            <li><strong>Powder:</strong> Most common form, varying purity levels</li>
            <li><strong>Pellets/Pills:</strong> Often pressed with inactive fillers</li>
            <li><strong>Crystals:</strong> Sometimes available as larger crystal fragments</li>
            <li><strong>Capsules:</strong> Pre-measured doses in gelatin capsules</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†ÔøΩEÔøΩECommon Adulterants & Confusion</h4>
          <p><strong>Often confused with:</strong> 5-APB (different effects), 6-APDB (similar name)</p>
          <p><strong>Common adulterants:</strong> Caffeine, inactive fillers, other benzofurans</p>
          <p><strong>Mis-sold as:</strong> MDMA, legal ecstasy, "plant food" or "research chemicals"</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">40-60mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">60-80mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">80-120mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">120-160mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">160mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Dosage Information</h4>
        <ul>
          <li><strong>Slower onset:</strong> Can take 1-3 hours to reach full effects</li>
          <li><strong>Long duration:</strong> 8-12 hour experience, plan accordingly</li>
          <li><strong>Individual variation:</strong> Sensitivity varies significantly between users</li>
          <li><strong>No redosing:</strong> Extremely long duration makes redosing dangerous</li>
          <li><strong>Body load:</strong> Higher doses associated with increased physical discomfort</li>
          <li><strong>First time:</strong> 60-80mg maximum to assess individual response</li>
        </ul>
      </div>
      
      <div class="route-specific">
        <h4>Route of Administration</h4>
        <ul>
          <li><strong>Oral (recommended):</strong> 60-150mg, 1-3 hour onset, full duration</li>
          <li><strong>Insufflated (not recommended):</strong> More caustic, shorter duration, increased body load</li>
          <li><strong>Sublingual:</strong> Faster onset but very bitter taste</li>
          <li><strong>Rectal:</strong> Faster onset, potentially more intense effects</li>
        </ul>
      </div>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral)</h4>
        <div class="timeline-item">
          <span class="time">T+1:00-3:00</span>
          <span class="effect">Onset - gradual energy increase, mood elevation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+3:00-6:00</span>
          <span class="effect">Peak - intense empathy, euphoria, energy</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-10:00</span>
          <span class="effect">Plateau - sustained effects, mild visuals possible</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+10:00-16:00</span>
          <span class="effect">Comedown - gradual decline, insomnia likely</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category empathogenic">
          <h4>üíñ Empathogenic Effects</h4>
          <ul>
            <li>Intense emotional openness and empathy</li>
            <li>Enhanced sociability and connection</li>
            <li>Feelings of love and acceptance</li>
            <li>Increased desire to communicate</li>
            <li>Enhanced appreciation for music</li>
            <li>Emotional euphoria and wellbeing</li>
          </ul>
        </div>
        
        <div class="effect-category stimulant">
          <h4>‚ö° Stimulant Effects</h4>
          <ul>
            <li>Increased energy and alertness</li>
            <li>Enhanced motivation and focus</li>
            <li>Decreased appetite</li>
            <li>Increased heart rate and blood pressure</li>
            <li>Insomnia and difficulty sleeping</li>
            <li>Jaw clenching and muscle tension</li>
          </ul>
        </div>
        
        <div class="effect-category psychedelic">
          <h4>üåÄ Mild Psychedelic Effects (Higher Doses)</h4>
          <ul>
            <li>Color enhancement and visual brightness</li>
            <li>Mild pattern recognition and geometric visuals</li>
            <li>Enhanced visual and auditory perception</li>
            <li>Slight time distortion</li>
            <li>Increased pattern appreciation</li>
            <li>Enhanced creativity and introspection</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùÅENegative Effects</h4>
          <ul>
            <li>Significant body load and physical discomfort</li>
            <li>Nausea and stomach upset (especially onset)</li>
            <li>Jaw tension and muscle stiffness</li>
            <li>Hyperthermia and overheating risk</li>
            <li>Insomnia lasting 12-24+ hours</li>
            <li>Anxiety and restlessness (comedown)</li>
            <li>Dehydration and increased thirst</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>6-APB functions as a triple monoamine releasing agent and reuptake inhibitor, similar to MDMA but with notable differences. It releases serotonin, dopamine, and norepinephrine while blocking their reuptake. The benzofuran ring system creates unique pharmacokinetic properties, resulting in longer duration and different receptor binding profiles compared to methylenedioxyamphetamines.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (5-HT transporter)</strong></span>
            <span class="affinity">High affinity</span>
            <span class="function">Primary empathogenic effects, emotional openness</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (NE transporter)</strong></span>
            <span class="affinity">Moderate-high affinity</span>
            <span class="function">Stimulant effects, energy, focus</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (DA transporter)</strong></span>
            <span class="affinity">Moderate affinity</span>
            <span class="function">Euphoria, reward pathway activation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT2A receptor</strong></span>
            <span class="affinity">Notable agonist activity</span>
            <span class="function">Mild psychedelic effects, visual enhancement</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT2B receptor</strong></span>
            <span class="affinity">Concerning agonist activity</span>
            <span class="function">Potential cardiac valve issues with chronic use</span>
          </div>
        </div>

        <h4>Benzofuran Ring System Properties</h4>
        <ul>
          <li><strong>Extended duration:</strong> Benzofuran ring resists metabolic breakdown, extending effects</li>
          <li><strong>Increased potency:</strong> More potent than MDMA on weight basis</li>
          <li><strong>Different metabolism:</strong> Lacks methylenedioxy bridge, different metabolic pathways</li>
          <li><strong>5-HT2B concerns:</strong> Higher 5-HT2B receptor affinity than MDMA</li>
          <li><strong>Body load:</strong> Benzofuran structure may contribute to increased physical side effects</li>
        </ul>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic metabolism via CYP enzymes, slower than MDMA</p>
          <p><strong>Half-life:</strong> 8-12 hours (significantly longer than MDMA)</p>
          <p><strong>Bioavailability:</strong> ~70-85% oral administration</p>
          <p><strong>Peak plasma:</strong> 2-4 hours after oral dose (delayed compared to MDMA)</p>
          <p><strong>Duration factors:</strong> Benzofuran ring system resists breakdown</p>
          <p><strong>Elimination:</strong> Primarily renal, with metabolites detectable for 48-72 hours</p>
        </div>

        <h4>Unique Pharmacological Concerns</h4>
        <div class="pharmacological-concerns">
          <p><strong>5-HT2B cardiotoxicity:</strong> Higher 5-HT2B receptor affinity raises cardiac valve concerns</p>
          <p><strong>Extended neurotransmitter depletion:</strong> Longer duration may increase neurotoxicity risk</p>
          <p><strong>Temperature regulation:</strong> Similar thermoregulatory disruption as MDMA but longer lasting</p>
          <p><strong>Limited human safety data:</strong> Less research on long-term effects compared to MDMA</p>
        </div>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Extended duration:</strong> 8-12+ hour experience, plan entire day/night</li>
            <li><strong>Cardiac concerns:</strong> 5-HT2B receptor activity may affect heart valves</li>
            <li><strong>Hyperthermia risk:</strong> Extended overheating potential</li>
            <li><strong>Severe insomnia:</strong> Sleep disruption lasting 12-24+ hours</li>
            <li><strong>Higher body load:</strong> More physical discomfort than MDMA</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°ÔøΩEÔøΩEEssential Precautions</h4>
          <ul>
            <li>Start with low doses (60-80mg maximum first time)</li>
            <li>Clear schedule for 24+ hours post-dosing</li>
            <li>Stay cool and hydrated throughout extended duration</li>
            <li>Have sleep aids available for comedown</li>
            <li>Avoid frequent use due to cardiac concerns</li>
            <li>Test substances - often mis-sold or adulterated</li>
            <li>Experienced sitter recommended for higher doses</li>
          </ul>
        </div>
      </div>

      <div class="cardiac-warning">
        <h4>üíî Cardiac Safety Concerns</h4>
        <div class="cardiac-safety-info">
          <ul>
            <li><strong>5-HT2B receptor activity:</strong> May contribute to cardiac valve fibrosis with repeated use</li>
            <li><strong>Avoid frequent use:</strong> Limit to rare occasions due to cardiac risks</li>
            <li><strong>Pre-existing conditions:</strong> Absolutely avoid if any heart conditions present</li>
            <li><strong>Long-term unknown:</strong> Limited data on chronic cardiovascular effects</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Absolute Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Any heart conditions, high blood pressure, seizure disorders, psychiatric conditions, are taking psychiatric medications, or have used within past 3 months.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Extremely Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome, hypertensive crisis</li>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome, unpredictable interactions</li>
            <li><strong>Tramadol:</strong> High seizure risk and serotonin syndrome</li>
            <li><strong>Other empathogens:</strong> MDMA, MDA - dangerous synergy</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Stimulants:</strong> Dangerous cardiovascular strain, extended effects</li>
            <li><strong>Psychedelics:</strong> Unpredictable interactions, extended duration</li>
            <li><strong>Alcohol:</strong> Increased dehydration, liver stress</li>
            <li><strong>Cannabis:</strong> May increase anxiety during long comedown</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Extreme Caution</h4>
          <ul>
            <li><strong>Benzodiazepines:</strong> May mask dangerous symptoms</li>
            <li><strong>Nitrous oxide:</strong> Risk of falls during extended intoxication</li>
            <li><strong>Other research chemicals:</strong> Unknown interaction profiles</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p><strong>Schedule I</strong> - Controlled as of 2014. Covered under Federal Analogue Act prior to specific scheduling.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p><strong>Class B</strong> - Controlled since 2013. Up to 5 years for possession, 14 years for supply.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE European Union</h4>
            <p><strong>Controlled</strong> - Most EU countries have specifically scheduled benzofurans including 6-APB.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Australia</h4>
            <p><strong>Schedule 9</strong> - Prohibited substance. Covered under amphetamine analog legislation.</p>
          </div>
        </div>
        
        <div class="research-chemical-legal-history">
          <h4>üìÖ Research Chemical Legal History</h4>
          <p>6-APB experienced a classic research chemical lifecycle: initial legal availability (2010-2013), growing popularity as "legal ecstasy," media attention, and rapid worldwide scheduling. It was often sold as "plant food" or "research chemical" with "not for human consumption" labels.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">2010</span>
          <p>First appeared in research chemical markets as "Benzofury"</p>
        </div>
        <div class="history-event">
          <span class="year">2011-2012</span>
          <p>Gained popularity as "legal MDMA" alternative in UK and Europe</p>
        </div>
        <div class="history-event">
          <span class="year">2013</span>
          <p>UK emergency bans benzofurans after media coverage</p>
        </div>
        <div class="history-event">
          <span class="year">2014</span>
          <p>US adds 6-APB to Schedule I, Europe follows suit</p>
        </div>
        <div class="history-event">
          <span class="year">2015+</span>
          <p>Availability drops significantly, remains in underground markets</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Research Chemical Era Impact</h4>
        <p>6-APB represented the peak of the "legal high" movement, marketed as "Benzofury" and sold openly in head shops and online. Its popularity demonstrated both the demand for MDMA alternatives and the rapid regulatory response to novel psychoactive substances. The substance became synonymous with the research chemical scene's attempt to recreate classic empathogen experiences.</p>
      </div>

      <div class="media-attention">
        <h4>Media & Regulatory Response</h4>
        <p>6-APB received significant negative media attention in the UK after several hospitalizations were attributed to "Benzofury" use. This media coverage accelerated regulatory responses across multiple countries, leading to its classification as a controlled substance within 3-4 years of its appearance.</p>
      </div>

      <div class="research-chemical-lessons">
        <h4>Research Chemical Market Lessons</h4>
        <p>The 6-APB story illustrates classic research chemical market dynamics: initial legal availability, marketing as safer alternatives to illegal drugs, growing popularity, adverse events, media attention, and rapid scheduling. It also highlighted the lack of quality control and proper dosing information in the RC market.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Cardiovascular Safety Studies</h4>
          <p>Limited research investigating 5-HT2B receptor activation and potential cardiac valve effects from benzofuran empathogens, comparing risk profiles to fenfluramine and other cardiotoxic serotonergics.</p>
        </div>
        
        <div class="research-item">
          <h4>Pharmacokinetic Research</h4>
          <p>Studies examining metabolism, duration, and elimination of benzofuran compounds to understand their extended duration compared to classical empathogens.</p>
        </div>
        
        <div class="research-item">
          <h4>Neurotoxicity Assessment</h4>
          <p>Research comparing benzofuran neurotoxicity profiles to MDMA, investigating whether extended duration increases risk of serotonergic damage.</p>
        </div>
        
        <div class="research-item">
          <h4>Novel Psychoactive Substance Monitoring</h4>
          <p>6-APB serves as a case study in NPS emergence, spread, and regulatory response, informing policy approaches to future novel substances.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Safety & Testing</h4>
        <ul>
          <li><a href="https://drugsdata.org/">DrugsData.org</a> - Lab testing service</li>
          <li><a href="https://dancesafe.org/">DanceSafe</a> - Reagent test kits</li>
          <li><a href="https://bunkpolice.com/">The Bunk Police</a> - Testing supplies</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Educational Resources</h4>
        <ul>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Comprehensive drug information</li>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and information</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Harm reduction forum</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Community</h4>
        <ul>
          <li><a href="https://reddit.com/r/researchchemicals">/r/ResearchChemicals</a> - Community discussion</li>
          <li><a href="https://psychedelicsafety.com/">Psychedelic Safety</a> - Crisis support</li>
          <li><a href="https://fireside-project.org/">Fireside Project</a> - Peer support</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="disclaimer-box">
    <h3>‚ö†ÔøΩEÔøΩEImportant Disclaimer</h3>
    <p>6-APB is a powerful and long-lasting empathogen with significant cardiovascular concerns and limited safety data. The extended duration (8-12+ hours) requires careful planning, and the 5-HT2B receptor activity raises questions about cardiac safety with repeated use. This information is provided for educational purposes only. The substance is illegal in most jurisdictions and carries significant legal and health risks.</p>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
    
    <!-- Only load interaction-checker.js on interaction checker page -->
    
</body>
</html>